Pinned Tweet
⭐ MPN Hub spotlight ⭐| Discover the challenges of anemia in myelofibrosis, the rationale for luspatercept, and the evolving management of MF-related anemia.
Learn more: bit.ly/4yBeji4
#MPN #MPNsm #MedNews #MedEd
Intended for healthcare professionals. by BMS. Funders are allowed no influence.
Learn more: bit.ly/4yBeji4
#MPN #MPNsm #MedNews #MedEd
Intended for healthcare professionals. by BMS. Funders are allowed no influence.
0
0
1
344
New publication 📝 Results from a retrospective study published in the @BrJHaem show that each 1 m/s higher baseline ePWV was independently associated with a 16% higher hazard of MACE in patients with ET or PV (HR, 1.16; 95% CI, 1.02–1.32; p = 0.025).
Learn more about MPN: bit.ly/4acXNKD
#MPN #MPNsm #PolycythemiaVera #EssentialThrombocythemia #MedNews #MedEd
Learn more about MPN: bit.ly/4acXNKD
#MPN #MPNsm #PolycythemiaVera #EssentialThrombocythemia #MedNews #MedEd
0
3
4
322
🚨 News 🚨
@FDA clears IND application for epetraborole for the treatment of PV, with a phase II global study planned to evaluate its efficacy and safety in adults with phlebotomy-dependent PV.
Read more: bit.ly/4yTEJeZ
#PolycythemiaVera #MPN #MPNsm #MedEd #MedNews
@FDA clears IND application for epetraborole for the treatment of PV, with a phase II global study planned to evaluate its efficacy and safety in adults with phlebotomy-dependent PV.
Read more: bit.ly/4yTEJeZ
#PolycythemiaVera #MPN #MPNsm #MedEd #MedNews
0
2
4
512
New publication 📝 Results from a retrospective study, published in Transplantation and Cellular Therapy, show the iMTSS framework outperforms all established systems for predicting post-transplant prognosis in patients with MF (concordance, 0.640; 95% CI, 0.616–0.662).
Learn t.co/OaRCvhRe89
#myelofibrosis #MPN #MPNsm #MedNews #MedEd
Learn t.co/OaRCvhRe89
#myelofibrosis #MPN #MPNsm #MedNews #MedEd
0
3
4
378
Learn more about diagnosing advanced #SystemicMastocytosis and assessing prognosis.
Explore the latest insights: bit.ly/4stX9Bm
#MPN #MPNsm #MedNews #MedEd
Explore the latest insights: bit.ly/4stX9Bm
#MPN #MPNsm #MedNews #MedEd
0
0
0
192
New publication 📝 Results from the phase III DALIAH trial, published in eClinicalMedicine, show pegylated interferon alpha-2 achieves superior long-term JAK2 V617F molecular responses vs hydroxyurea in patients with MPN who remained on long-term therapy (67% vs 35% at 60 months; about MPN: bit.ly/4acXNKD
#MPN #MPNsm #MedNews #MedEd
#MPN #MPNsm #MedNews #MedEd
0
5
9
491
Explore current guidelines and trends in the diagnosis and prognostic assessment of advanced #SystemicMastocytosis.
Learn more: bit.ly/4stX9Bm
#MPN #MPNsm #MedNews #MedEd
Learn more: bit.ly/4stX9Bm
#MPN #MPNsm #MedNews #MedEd
0
0
0
179
New publication 📝 Results from a retrospective study, published in Annals of Hematology, show that an AI-based model classified BCR::ABL1-negative MPN subtypes from bone marrow smears with a ROC-AUC of 0.84 and mean accuracy of 0.75.
Learn more about MPN: bit.ly/4acXNKD
#MPN #MPNsm #MedNews #MedEd
Learn more about MPN: bit.ly/4acXNKD
#MPN #MPNsm #MedNews #MedEd
1
0
5
303
Learn about novel combination approaches and emerging treatment strategies in myelofibrosis.
Read more here: bit.ly/4jAj3R2
#MPN #MPNsm #MedNews #MedEd #myelofibrosis
Read more here: bit.ly/4jAj3R2
#MPN #MPNsm #MedNews #MedEd #myelofibrosis
0
0
0
232
New publication 📝 Results from a phase II trial, published in @Haematologica, show azacitidine + ruxolitinib achieved an ORR of 78% and 43% in patients with chronic phase and accelerated phase MF, respectively.
Learn more about MF: bit.ly/4snWHUc
#myelofibrosis #MPN #MPNsm #MedNews #MedEd
Learn more about MF: bit.ly/4snWHUc
#myelofibrosis #MPN #MPNsm #MedNews #MedEd
1
4
8
511
Explore the MPN Hub’s latest focused review on novel combination treatment strategies for MF.
Read more here: bit.ly/4jAj3R2
#MPN #MPNsm #MedNews #MedEd #myelofibrosis
Read more here: bit.ly/4jAj3R2
#MPN #MPNsm #MedNews #MedEd #myelofibrosis
0
0
1
221
New publication 📝 Results from an observational study, published in @NursingOpen, demonstrate that fatigue is the most prevalent symptom in MPN, affecting 72% of patients and significantly impairing global health (OR, 4.7; p < 0.001).
Learn more about MPN: htt#MPNsm #MPN #PolycythemiaVera #EssentialThrombocythemia #Myelofibrosis #MedNews #MedEd
Learn more about MPN: htt#MPNsm #MPN #PolycythemiaVera #EssentialThrombocythemia #Myelofibrosis #MedNews #MedEd
0
3
4
249
CONGRESS | #IACH2026 | PRESENTATION
Anna Godfrey discusses emerging precision therapies in #EssentialThrombocythemia.
Godfrey presents several patient case studies representing distinct clinical scenarios, and how treatment can be personalized to improve outcomes. She reviews g precision therapies that may be applicable in these settings. Godfrey emphasizes that individualization is central to precision medicine in ET, and that while conventional management based on vascular risk stratification and event reduction remains fundamental to clinical practice, it may no longer be the primary treatment goal for all patients.
Follow our live feed for more updates: bit.ly/4rXTziy
Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.
#MPN #MPNsm #MedEd #MedCongress @TheIACH
Anna Godfrey discusses emerging precision therapies in #EssentialThrombocythemia.
Godfrey presents several patient case studies representing distinct clinical scenarios, and how treatment can be personalized to improve outcomes. She reviews g precision therapies that may be applicable in these settings. Godfrey emphasizes that individualization is central to precision medicine in ET, and that while conventional management based on vascular risk stratification and event reduction remains fundamental to clinical practice, it may no longer be the primary treatment goal for all patients.
Follow our live feed for more updates: bit.ly/4rXTziy
Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.
#MPN #MPNsm #MedEd #MedCongress @TheIACH
0
2
4
390
CONGRESS | #IACH2026 | PRESENTATION
Naveen Pemmaraju shares evidence for use of hepcidin mimetics in management of patients with #PolycythemiaVera.
Pemmaraju presents clinical trial data on rusfertide for treatment of patients with PV, as well as data from emerging hepcidin . He highlights remaining limitations and questions for use in PV, such as long-term side effects and FU time.
Follow our live feed for more updates: bit.ly/4rXTziy
Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.
#MPN #MPNsm #MedEd #MedCongress @TheIACH
Naveen Pemmaraju shares evidence for use of hepcidin mimetics in management of patients with #PolycythemiaVera.
Pemmaraju presents clinical trial data on rusfertide for treatment of patients with PV, as well as data from emerging hepcidin . He highlights remaining limitations and questions for use in PV, such as long-term side effects and FU time.
Follow our live feed for more updates: bit.ly/4rXTziy
Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.
#MPN #MPNsm #MedEd #MedCongress @TheIACH
0
1
5
300
CONGRESS | #IACH2026 | PRESENTATION
Lina Benajiba discusses the use of IFN in the management of patients with #PolycythemiaVera and #EssentialThrombocythemia.
Benajiba presents data from key trials supporting use of IFN in patients with PV and ET. She notes that IFN is ine therapy in patients with high-risk PV, as well as those with low-risk PV and high-risk features, and following hydroxyurea failure. In ET, she suggests that IFN should be used in young patients, those planning pregnancy, and after hydroxyurea failure. She emphasizes that achieving a hematologic response remains the minimum treatment goal, while molecular response is emerging as a marker of disease modification.
Follow our live feed for more updates: bit.ly/4rXTziy
Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.
#MPN #MPNsm #MedEd #MedCongress @TheIACH
Lina Benajiba discusses the use of IFN in the management of patients with #PolycythemiaVera and #EssentialThrombocythemia.
Benajiba presents data from key trials supporting use of IFN in patients with PV and ET. She notes that IFN is ine therapy in patients with high-risk PV, as well as those with low-risk PV and high-risk features, and following hydroxyurea failure. In ET, she suggests that IFN should be used in young patients, those planning pregnancy, and after hydroxyurea failure. She emphasizes that achieving a hematologic response remains the minimum treatment goal, while molecular response is emerging as a marker of disease modification.
Follow our live feed for more updates: bit.ly/4rXTziy
Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.
#MPN #MPNsm #MedEd #MedCongress @TheIACH
1
3
7
661
CONGRESS | #IACH2026 | PRESENTATION
Deepti Radia discusses current trends in advanced #SystemicMastocytosis treatment and how risk-adapted therapy could be applied across other MPN.
Radia highlights how KIT inhibitors have changed the treatment landscape in AdvSM, while novel xpand the treatment armamentarium. She notes that SM-AHN remains challenging to manage in clinical practice. Drawing parallels between AdvSM and MF, she suggests that risk-adapted treatment strategies could be extended to other MPN, with assessment of molecular risk, disease progression risk, and clonal complexity representing a future approach to treatment decision-making.
Follow our live feed for more updates: bit.ly/4rXTziy
Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.
#MPN #MPNsm #MedEd #MedCongress @TheIACH
Deepti Radia discusses current trends in advanced #SystemicMastocytosis treatment and how risk-adapted therapy could be applied across other MPN.
Radia highlights how KIT inhibitors have changed the treatment landscape in AdvSM, while novel xpand the treatment armamentarium. She notes that SM-AHN remains challenging to manage in clinical practice. Drawing parallels between AdvSM and MF, she suggests that risk-adapted treatment strategies could be extended to other MPN, with assessment of molecular risk, disease progression risk, and clonal complexity representing a future approach to treatment decision-making.
Follow our live feed for more updates: bit.ly/4rXTziy
Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.
#MPN #MPNsm #MedEd #MedCongress @TheIACH
0
0
2
216
CONGRESS | #IACH2026 | PRESENTATION
Jason Gotlib discusses key lessons learned from use of KIT inhibitors in #SystemicMastocytosis and remaining questions facing patient management.
Gotlib highlights the importance of a KIT detection method with a high sensitivity, notes that be well-managed with KIT inhibitors, and emphasizes the need for early recognition of AHN, which can challenge clinical decision-making and worsen outcomes in patients with SM.
Follow our live feed for more updates: bit.ly/4rXTziy
Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.
#MPN #MPNsm #MedEd #MedCongress @TheIACH
Jason Gotlib discusses key lessons learned from use of KIT inhibitors in #SystemicMastocytosis and remaining questions facing patient management.
Gotlib highlights the importance of a KIT detection method with a high sensitivity, notes that be well-managed with KIT inhibitors, and emphasizes the need for early recognition of AHN, which can challenge clinical decision-making and worsen outcomes in patients with SM.
Follow our live feed for more updates: bit.ly/4rXTziy
Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.
#MPN #MPNsm #MedEd #MedCongress @TheIACH
0
0
1
208
CONGRESS | #IACH2026 | PRESENTATION
Juan Carlos Hernandez-Boluda discusses who should be referred for allo-HSCT transplant in #myelofibrosis, and who may be overlooked for transplantation.
Hernandez-Boluda suggests that, alongside the EBMT/ELN guidelines, patients with levated transplantation risk should be considered for allo-HSCT. He highlights the value of blood blasts and cytogenetic abnormalities in identifying suitable candidates, and notes that high-risk mutations not captured by MIPSS70 may also inform referral decisions. He emphasizes that early referral for transplantation consultation is recommended for all potential candidates.
Follow our live feed for more updates: bit.ly/4rXTziy
Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.
#MPN #MPNsm #MedEd #MedCongress @TheIACH
Juan Carlos Hernandez-Boluda discusses who should be referred for allo-HSCT transplant in #myelofibrosis, and who may be overlooked for transplantation.
Hernandez-Boluda suggests that, alongside the EBMT/ELN guidelines, patients with levated transplantation risk should be considered for allo-HSCT. He highlights the value of blood blasts and cytogenetic abnormalities in identifying suitable candidates, and notes that high-risk mutations not captured by MIPSS70 may also inform referral decisions. He emphasizes that early referral for transplantation consultation is recommended for all potential candidates.
Follow our live feed for more updates: bit.ly/4rXTziy
Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.
#MPN #MPNsm #MedEd #MedCongress @TheIACH
0
3
8
558